Windlas Biotech: The Board approved inter alia financial results for the quarter and half year ended September 30 2026
Windlas Biotech (WINDLAS) filed a disclosure titled "The Board approved inter alia financial results for the quarter and half year ended September 30 2026". The company is valued at about ₹1,815 crore.
What happened
Windlas Biotech (WINDLAS) filed a disclosure with the exchanges on 5 November 2026 at 04:18 PM titled "The Board approved inter alia financial results for the quarter and half year ended September 30 2026".
Company snapshot
Windlas Biotech is a small-cap company, with a market value of about ₹1,815 crore.
The stock last traded at ₹879.6, against a 52-week range of ₹697.4–₹1,181.9 (25.6% below the high).
Before this filing the shares had moved −18.7% over the month and +2.0% over three months. Average daily turnover over the last 20 sessions was about ₹6.9 crore.
Promoters held 63.31% at the end of Q1 FY27. Foreign institutions owned 2.04% and domestic institutions 9.84%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 210 | 17.7 | 8.43 |
| Q2 FY26 | 222 | 17.8 | 8.48 |
| Q3 FY26 | 233 | 15 | 7.12 |
| Q4 FY26 | 238 | 16 | 7.58 |
| Q1 FY27 | 248 | 17.7 | 8.46 |
What history shows
BCEIE's records show 2 previous results filings from the company since May 2026.
Market-wide, 10,790 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 5 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.